



Summit Corporation plc
(“Summit plc” or “the Company”)

SUMMIT PLC SIGNS RESEARCH AGREEMENT FOR ZEBRAFISH TECHNOLOGY PLATFORM

Oxford, UK, 13 October 2008 – Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, announces that it has signed a non-exclusive research agreement with the healthcare and pharmaceutical company Johnson & Johnson PTE LTD to explore and develop the use of zebrafish drug screening in drug discovery and development.

Under the terms of the agreement, Summit will receive an undisclosed amount over three years to support the development of new assays using the zebrafish platform. The platform is used to screen drug candidates for a broad range of toxicity and safety issues. The research will be undertaken at a new state-of-the-art zebrafish facility in Singapore and will be established and maintained by Summit as part of this agreement.

Summit expects the facility in Singapore to be fully operational early in 2009, when it will primarily undertake assay development work in accordance with the agreement. In addition, Summit will use Singapore, already a centre of excellence in zebrafish research, as a base to target new markets in the Far East and expand its current zebrafish screening services business.

Steven Lee, PhD, Chief Executive Officer of Summit commented: “I am pleased Summit will be extending the excellent relationship we have established in our zebrafish technology through the signing of this longer-term agreement. This partnership is an important milestone for Summit and is a natural follow-on from previous pilot studies conducted with Johnson & Johnson PTE LTD. Beyond this agreement, I anticipate additional assay screening revenues and assay development work plus further services revenues from other third party clients.

“I believe this agreement demonstrates continued interest in the value zebrafish can bring to the drug discovery process and will enhance one of our two technology platforms that support our drug programme business. We look forward to working closely with them on developing this technology over the next few years.”

- ENDS -

For more information, please contact:

Summit plc

Steven Lee, PhD, Chief Executive Officer

Richard Pye, PhD, Investor Relations

Tel: +44 (0)1235 443951; +44 (0)7825 313476

Citigate Dewe Rogerson

Mark Swallow, PhD / David Dible / Emma Palmer Foster

Tel: +44 (0)207 638 9571

Panmure Gordon

Andrew Burnett / Rakesh Sharma (Corporate Finance)

Ashton Clanfield (Corporate Broking)

Tel: +44 (0)207 459 3600

About Summit plc

Summit plc is a leading UK biotechnology company with a broad preclinical and clinical pipeline, two world-leading technology platforms and an innovative business model that is expected to generate sustainable value for investors.

Summit is developing multiple drug programmes that target unmet medical needs from which it intends to generate value by out-licensing attractive late preclinical or early clinical stage programmes in return for upfront, milestone and royalty payments. Summit uses its scientific expertise to target orphan diseases, neuro-disorders and infectious diseases. Summit has signed a major licensing agreement with BioMarin in Duchenne muscular dystrophy and has co-development agreements with Evolva (infectious diseases), Orient Pharma (sialorrhoea) and the Lilly TB Drug Discovery Initiative (tuberculosis)

Underpinning Summit's drug pipeline are two innovative technology platforms: carbohydrate chemistry and zebrafish biology. These platforms support existing programmes and also will be the source of future programmes to replenish Summit's drug pipeline. These platform technologies also form the basis of the Company's profitable service business.

The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM. Further information about the company is available at www.summitplc.com.